Education
About Us
Working with TipRanks
Follow Us
Advaxis (ADXS)
OTHER OTC:ADXS
ADXS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.02 - $0.78
Previous CloseN/A
Volume3.00
Average Volume (3M)486.00
Market Cap
$1.28M
Enterprise ValueN/A
Total Cash (Recent Filing)$32.71M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-6.76
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding42,633,400
10 Day Avg. Volume382
30 Day Avg. Volume486
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)98.38
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Advaxis News
PremiumCompany Announcements
Advaxis Executive Reshuffle Following Asset Sale
PremiumCompany Announcements
Advaxis Enhances Operations Through Strategic Asset Sale
PremiumCompany Announcements
Advaxis Clarifies CMO Bonus Terms Amid Asset Sale
PremiumCompany Announcements
Advaxis Asset Sale Approved by Majority Shareholder Vote
PremiumCompany Announcements
Advaxis Executes Strategic Unregistered Equity Sales---
Ownership Overview
58.95%
Insiders
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ADXS FAQ
What was Advaxis’s price range in the past 12 months?
Advaxis lowest stock price was $0.02 and its highest was $0.78 in the past 12 months.
What is Advaxis’s market cap?
Advaxis’s market cap is $1.28M.
When is Advaxis’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Advaxis’s earnings last quarter?
Currently, no data Available
Is Advaxis overvalued?
According to Wall Street analysts Advaxis’s price is currently Overvalued.
Does Advaxis pay dividends?
Advaxis does not currently pay dividends.
What is Advaxis’s EPS estimate?
Advaxis’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Advaxis have?
Advaxis has 42,633,400 shares outstanding.
What happened to Advaxis’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Advaxis?
Currently, no hedge funds are holding shares in ADXS
---
Company Description
Advaxis
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
---
ADXS Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Agenus
―
Immutep
―
Northwest Biotherapeutics
―
Iovance Biotherapeutics
―
Cellectar Biosciences
―
---